AU2002320847B2 - Process for the production of the piperidine derivative fexofenadine - Google Patents

Process for the production of the piperidine derivative fexofenadine Download PDF

Info

Publication number
AU2002320847B2
AU2002320847B2 AU2002320847A AU2002320847A AU2002320847B2 AU 2002320847 B2 AU2002320847 B2 AU 2002320847B2 AU 2002320847 A AU2002320847 A AU 2002320847A AU 2002320847 A AU2002320847 A AU 2002320847A AU 2002320847 B2 AU2002320847 B2 AU 2002320847B2
Authority
AU
Australia
Prior art keywords
alkyl
formula
compound
mixture
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002320847A
Other languages
English (en)
Other versions
AU2002320847A1 (en
Inventor
Richard Charles
Ryan Huddleston
Collin Schroeder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of AU2002320847A1 publication Critical patent/AU2002320847A1/en
Assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH reassignment SANOFI-AVENTIS DEUTSCHLAND GMBH Request for Assignment Assignors: AVENTIS PHARMA DEUTSCHLAND GMBH
Application granted granted Critical
Publication of AU2002320847B2 publication Critical patent/AU2002320847B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2002320847A 2001-06-15 2002-06-12 Process for the production of the piperidine derivative fexofenadine Ceased AU2002320847B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29839701P 2001-06-15 2001-06-15
US60/298,397 2001-06-15
PCT/EP2002/006424 WO2002102776A1 (en) 2001-06-15 2002-06-12 Process for the production of the piperidine derivative fexofenadine

Publications (2)

Publication Number Publication Date
AU2002320847A1 AU2002320847A1 (en) 2003-05-15
AU2002320847B2 true AU2002320847B2 (en) 2007-09-20

Family

ID=23150325

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002320847A Ceased AU2002320847B2 (en) 2001-06-15 2002-06-12 Process for the production of the piperidine derivative fexofenadine

Country Status (22)

Country Link
US (2) US6743941B2 (enExample)
EP (1) EP1401816B1 (enExample)
JP (1) JP4344230B2 (enExample)
KR (1) KR100903285B1 (enExample)
CN (1) CN1229347C (enExample)
AR (1) AR037005A1 (enExample)
AT (1) ATE386021T1 (enExample)
AU (1) AU2002320847B2 (enExample)
BR (1) BR0210410A (enExample)
CA (1) CA2450313C (enExample)
DE (1) DE60225008T2 (enExample)
DK (1) DK1401816T3 (enExample)
ES (1) ES2298384T3 (enExample)
HU (1) HUP0401125A2 (enExample)
IL (2) IL159304A0 (enExample)
MX (1) MXPA03010960A (enExample)
NO (1) NO20035572L (enExample)
NZ (1) NZ530153A (enExample)
PL (1) PL364369A1 (enExample)
PT (1) PT1401816E (enExample)
WO (1) WO2002102776A1 (enExample)
ZA (1) ZA200308697B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7498443B2 (en) * 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of carebastine
US7498345B2 (en) * 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of piperidine derivatives
CN100453522C (zh) * 2005-01-26 2009-01-21 中国科学技术大学 4-[4-(1-乙氧基酰基-1-甲基乙基苯)]-4-氧代丁酸的制备方法
WO2007135693A2 (en) * 2006-05-18 2007-11-29 Ind-Swift Laboratories Limited Intermediates useful for the preparation of antihistaminic piperidine derivative
ITMI20061492A1 (it) * 2006-07-27 2008-01-28 Archimica Srl Processo per la preparazione di fexofenadina.
ITMI20061491A1 (it) * 2006-07-27 2008-01-28 Archimica Srl Processo per la preparazione di fexofenadina.
CN102070570A (zh) * 2009-11-21 2011-05-25 浙江华海药业股份有限公司 一种非索非那定中间体2-甲基-2(4-(2-氧代四氢呋喃-3-羰基)苯基)丙氰及其盐的制备方法
CN102070490B (zh) * 2009-11-21 2014-07-30 浙江华海药业股份有限公司 一种非索非那定中间体2-(4-(4-羟基丁酰基)苯基)-2-甲基丙氰的制备方法
RU2017139727A (ru) 2015-06-15 2019-07-16 АСАНА БАЙОСАЙЕНСИЗ, ЭлЭлСи Гетероциклические ингибиторы erk1 и erk2 и их применение для лечения злокачественного новообразования
CN104876853B (zh) * 2015-06-17 2017-06-16 苏州卫生职业技术学院 盐酸非索非那定的合成方法
WO2017068129A1 (en) 2015-10-22 2017-04-27 Sanofi-Aventis Deutschland Gmbh Process for the preparation of fexofenadine and of intermediates used therein
EP3600302A4 (en) 2017-03-29 2020-12-30 United States Government as Represented by The Department of Veterans Affairs METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
CN120204227A (zh) 2019-10-28 2025-06-27 阿沙纳生物科学公司 使用erk1和erk2的杂环抑制剂的改善的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0347123A2 (en) * 1988-06-17 1989-12-20 Fisons Corporation Dibenzo-cycloheptenyl, -cycloheptyl and -oxepinyl amines having antihistaminic properties
AT392782B (de) * 1985-09-27 1991-06-10 Ind Chimica Srl Verfahren zur herstellung von alpha-(p-tent.- butylphenyl)-4-(hydroxydiphenylmethyl)-1- piperidinobutanol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2946809A1 (de) * 1979-11-20 1981-06-11 A. Nattermann & Cie GmbH, 5000 Köln 4-phenyl-4-oxo-buttersaeuren, deren salze und ester, verfahren zu deren herstellung und diese enthaltende arzneimittel
IT1249684B (it) 1991-07-19 1995-03-09 Sorin Biomedica Spa Epitopi della proteina env del virus dell'epatite c.
HU226561B1 (en) * 1992-04-10 2009-04-28 Merrell Dow Pharma Process for preparation 4-diphenylmethyl piperidine derivatives and the novel intermediates thereof
HU226559B1 (en) 1993-06-24 2009-03-30 Amr Technology Process for the production of piperidine derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT392782B (de) * 1985-09-27 1991-06-10 Ind Chimica Srl Verfahren zur herstellung von alpha-(p-tent.- butylphenyl)-4-(hydroxydiphenylmethyl)-1- piperidinobutanol
EP0347123A2 (en) * 1988-06-17 1989-12-20 Fisons Corporation Dibenzo-cycloheptenyl, -cycloheptyl and -oxepinyl amines having antihistaminic properties

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Hester J B et al. N-Uomega-amino-1-hydroxyalkyl)phenylmethanesulfonamide derivatives with class III antiarrhythmic activity Journal of Medicinal Chemistry, American Chemical Society, vol 34, no. 1, 1991, pages 308-315 *

Also Published As

Publication number Publication date
KR20040010720A (ko) 2004-01-31
ZA200308697B (en) 2004-09-03
PT1401816E (pt) 2008-04-08
AR037005A1 (es) 2004-10-20
CN1229347C (zh) 2005-11-30
US7235665B2 (en) 2007-06-26
NZ530153A (en) 2005-07-29
DE60225008T2 (de) 2009-01-29
WO2002102776A1 (en) 2002-12-27
ATE386021T1 (de) 2008-03-15
MXPA03010960A (es) 2004-02-27
HK1063795A1 (en) 2005-01-14
US6743941B2 (en) 2004-06-01
IL159304A (en) 2010-02-17
US20040198983A1 (en) 2004-10-07
CN1516689A (zh) 2004-07-28
CA2450313C (en) 2010-08-10
JP4344230B2 (ja) 2009-10-14
US20030105329A1 (en) 2003-06-05
EP1401816B1 (en) 2008-02-13
PL364369A1 (en) 2004-12-13
JP2005502603A (ja) 2005-01-27
KR100903285B1 (ko) 2009-06-17
NO20035572L (no) 2004-02-16
DK1401816T3 (da) 2008-06-09
ES2298384T3 (es) 2008-05-16
HUP0401125A2 (hu) 2004-09-28
BR0210410A (pt) 2004-08-17
EP1401816A1 (en) 2004-03-31
DE60225008D1 (de) 2008-03-27
IL159304A0 (en) 2004-06-01
NO20035572D0 (no) 2003-12-12
CA2450313A1 (en) 2002-12-27

Similar Documents

Publication Publication Date Title
US4739101A (en) Method for the preparation of fibrates
CA2450313C (en) Process for the production of the piperidine derivative fexofenadine
JP2011046703A (ja) ニトリル化合物、カルボン酸化合物又はカルボン酸エステル化合物の製法
AU2002320847A1 (en) Process for the production of the piperidine derivative fexofenadine
KR100669823B1 (ko) 2-(4-클로로벤조일아미노)-3-[2(1ｈ)-퀴놀리논-4-일]프로피온산의 제조방법 및 그 중간체
US5675009A (en) Process for piperidine derivatives
ES2226185T3 (es) Procedimiento para la preparacion de 1,4-dihidropiridinas y compuestos utilizados en dicho procedimiento.
US20110269962A1 (en) Process for preparing statins
KR101063146B1 (ko) 피타바스타틴 중간체의 제조방법 및 이를 이용한 피타바스타틴 헤미 칼슘염의 제조방법
JP7252978B2 (ja) ２－（１－（ｔｅｒｔ－ブトキシカルボニル）ピペリジン－４－イル）安息香酸を調製するためのプロセス
EP0996616B1 (en) Process and a novel intermediate for the preparation of flecainide
KR20120125190A (ko) ｔ-부틸 2-((4Ｒ,6Ｓ)-6-포밀-2,2-디메틸-1,3-디옥산-4-일)아세테이트의 제조방법
JPH0742269B2 (ja) ４−アルコキシ−３−ピロリン−２−オン−１−イル−酢酸アルキルエステルおよびその製造方法
US20040077900A1 (en) Process for the preparation of a highly pure pharmaceutical intermediate, 4-(cyclopropylcarbonyl)-alpha, alpha-dimethylphenylacetic acid
KR100540153B1 (ko) o-클로로메틸-페닐글리옥실산유도체의제조방법
JP2004521942A5 (enExample)
JP2003515600A (ja) ｛２−［４−（α−フェニル−ｐ−クロロベンジル）ピペラジン−１−イル］エトキシ｝酢酸の製法及びそのための新規な中間体
JPWO2005058860A1 (ja) ４−置換又は非置換テトラヒドロピラン−４−カルボン酸化合物又はそのエステル化合物の製法
JP4207201B2 (ja) Ｎ−アルコキシカルボニルピペリジン誘導体の製造方法、並びにその原料化合物及びその製造方法
EP1080062B1 (en) Process for the preparation of 2-hydroxyalkyl halophenones
EP4472950B1 (en) Process for making a taste-modifying compound
US20020133013A1 (en) Process for making cyanomethyl ester precursors of flecainide
KR100413172B1 (ko) 퀴놀리논 유도체의 제조방법
EP1400511A1 (en) Methods of producing n-alkoxycarbonylpiperidine derivatives and intermediates therefor
HU204771B (en) Process for producing anilinofumarates from chloromaleates or chlorofumarates or from their mixture

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH

Free format text: FORMER APPLICANT(S): AVENTIS PHARMA DEUTSCHLAND GMBH

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired